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Abstract
Background—Very little is known about influenza viruses circulating in the Democratic 
Republic of Congo (DRC). We aim to characterize genetically and antigenically Influenza 
A(H3N2) and A(H1N1)pdm09 viruses circulating in the country.
Methods—From August to December 2014, specimens were collected from patients with 
influenza like-illness (ILI) or severe acute respiratory infection (SARI) in various surveillance 
sites. Specimens were tested using real time reverse transcription polymerase chain reaction (RT-
PCR) method for the detection of influenza viruses. Positive influenza samples with a cycle 
threshold (Ct) <30 were genetically and antigenically characterized.
Results—32 samples tested were found positive to influenza A with Ct <30. At CDC Atlanta, 28 
out of 32 samples (88%) were tested positive for influenza A virus, including 26 seasonal 
influenza A viruses subtype H3N2 and 2 pandemic influenza A viruses subtype H1N1pdm 2009. 
The majority of influenza A(H3N2) viruses were antigenically related to the A/Switzerland/
9715293/2013 vaccine virus, while two influenza A(H1N1)pdm09 isolates were antigenically 
characterized as A/California/07/2009-like. All A(H3N2) and A(H1N1)pdm09 virus isolates 
characterized were sensitive to oseltamivir and zanamivir.
Conclusion—Two genetically distinct influenza subtypes were co-circulating in the DRCongo. 
Effective measures against influenza have been suggested.
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1. Introduction
Influenza is a contagious respiratory disease caused by the influenza virus, a member of the 
Orthomyxoviridae family of RNA viruses which have a segmented genome. There are three 
types of influenza viruses (A, B and C), originally distinguished on the basis of their internal 
nucleoprotein and matrix proteins. Influenza virus A and B cause annual, recurrent 
outbreaks in tropical and sub-tropical countries leading to high morbidity and mortality [1], 
especially in children and the elderly. It is estimated that one million deaths each year are 
due virus infection [2]. According to the World Health Organization (WHO), about20%of all 
deaths among children aged <5 years are attributable to influenza-like illnesses (ILI) [3], and 
the majority of those deaths occur in Africa and Southeast Asia [3, 4].
Seasonal influenza viruses are a population of virus variants, mainly existing as a result of 
antigenic drift, the accumulation of point mutations in the hemagglutinin (HA) and 
neuraminidase (NA) surface glycoprotein due to the lack of virus RNA polymerase complex 
pro of reading activity [5]. The HA is known to be the main antigenic determinant of the 
host’s neutralizing immune response [6,7,8] and is under selective pressure for antigenic 
shift, the process by which new virus variants emerge from genetic reassortment among 
influenza viruses infecting human and animal populations. Antigenic shift results in virus 
evasion of the preexisting immunity of the host [9]. In addition, genetic mechanisms like 
nucleic acid substitution, gene insertion and deletion have been reported to contribute with 
influenza virus variability [9, 10].
Previous studies have shown that influenza is a major contributor of respiratory illness in 
tropical and subtropical regions worldwide, with more complex patterns of influenza 
seasonality in Africa and southern Asia [11, 12, and 13]. Tropical countries closer to the 
equator have year-round influenza activity without a distinct seasonal peak [14, 15, 16, 17]. 
However, South Africa, Zambia [18], and Senegal [19] seem to have well-defined patterns of 
seasonality similar to other countries with temperate climates [17]. Furthermore, 
Madagascar described a yearly circulation of influenza with two distinct peaks, one that 
corresponds to the northern hemisphere winter (January–March) and a second that 
corresponds to the southern hemisphere winter (June–October) [18]. Unfortunately, the 
limited data available from sub-Saharan Africa makes it difficult to comprehensively map 
and define the seasonality of influenza in the region. The seasonality of influenza coupled 
with virus genetic and antigenic variation present challenges to the selection of potential 
virus candidates to be used in the formulation of influenza vaccines. Timely and 
geographically comprehensive virologic surveillance involving genetic and antigenic 
analysis of circulating strains is critical to maintaining the effectiveness of the influenza 
vaccine [20].
Although some countries, such as Madagascar and Senegal, have led national influenza 
surveillance for many years [21, 22], several countries in the African continent began 
conducting influenza surveillance recently. In DRCongo, the influenza surveillance system 
based on laboratory analysis was introduced in 2008 and reported that influenza is present 
year-round associated with some peaks related to the rainy season [23]. Despite the 
increased interest on improving influenza surveillance in Africa, the available genetic and 
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epidemiological data are still insufficient to understand disease dynamics in the region. Due 
to the limited knowledge on influenza virus dynamics in Africa and to contribute in the 
improvement of the DRC surveillance system, we sought to identify and characterize for the 
first time the influenza viruses circulating in the Democratic Republic of Congo during the 
period from August to December of 2014.
2. Materials and Methods
2.1. Ethical Considerations
Specimens and data were collected as part of national public health sentinel surveillance 
systems, which is considered a non research activity. Influenza sentinel surveillance 
protocols were adapted from World Health Organization (WHO) guidelines with support 
from the national influenza program at the DRCongo Ministry of health. This protocol was 
implemented as part of routine public health surveillance by the Ministry of Health and was 
therefore considered a service and not subject to human subjects review. Before collecting 
each specimen, physicians explained the purpose of the surveillance system. After that, 
patients could refuse to participate. Oral consent was documented in the patient’s study 
records. Specimens and data were processed anonymously.
2.2. Study area and Sample collection
Nasal, throat and nasopharyngeal swab samples from all enrolled patients presenting with 
severe acute respiratory infectious (SARI) or influenza-like-illness (ILI) were collected from 
various surveillance sites selected in DRC and sent to the Influenza National Reference 
Laboratory at INRB using 3-mL cryovials containing Viral Transport Medium (Copan 
diagnostics-Murrietaca-USA).
Throat and nasopharyngeal swab specimens were collected from the same patient; both 
swabs were placed in the same cryovial. The specimens were kept refrigerated at 4°C, until 
they were packaged using a triple packaging system at the sentinel site. The specimens were 
then sent in refrigerated cool boxes to the INRB within 72 hours after packaging, where they 
were divided into 3 aliquots. One aliquot was used for molecular analysis; two others were 
stored at −80°C for further analysis and safeguard.
2.3. Laboratory analysis
• RNA extraction—Ribonucleic acid (RNA) extractions were performed at INRB, after 
dividing each sample in three cryovials containing 1 ml aliquots. One aliquot was 
immediately used for RNA extraction, while the other two aliquots were stored at −80°C for 
future use. Nucleic acid was extracted from 140 μl of aliquot, using the QIAamp® Viral 
RNA Mini Kit (Qiagen, Germany) according to the manufacturer’s instructions. Purified 
RNA was stored at −80°C in aliquots.
• Amplification by Reverse Transcription Polymerase Chain Reaction (RT-PCR)
—The RT-PCR technique is used as a rapid and sensitive method for the detection of 
influenza viruses in clinical and virus isolate samples. All samples were screened for 
influenza A and B viruses by one step real- time reverse transcription polymerase chain 
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reaction. The influenza A one–step real-time RT-PCR was performed using primers for 
matrix gene (forward: 5′-GACCRATCCTGTCACCTCTGAC-3′; reverse: 5′-AGGGCA 
TTYTGGACAAAKCGTCTA-3′; probe: 5′-FAM- TGCAGTCCTCGCTCACTGGGCACG-
MGB- 3′) provided by the CDC in Atlanta, GA and according to the provided CDC 
protocol. Type A and B influenza matrix genes were amplified.
Reaction mixtures (25μL) were prepared using the Ag- Path-ID™ One-Step RT-PCR Kit 
(Ambion, USA) and contained final concentrations: 12.5 μl of 2X RT-PCR Buffer, 0.25 μl of 
40 μM reverse primer, 0.25 μl of 40 μM forward primers, 0.25 μl of 10 μM of specific probe, 
1μl of 25X RT–PCR enzyme (Taq DNA polymerase and reverse transcriptase) and 5 μl of 
nucleic acid. Amplification was performed on ABI7500 Fast Real-time PCR System 
(Applied Biosystems, USA) with the following cycling conditions: 40°C for 10 min, 95°C 
for 10 min and 95°C for 15s followed by 55°C for 60s (45 cycles). Each specimen was also 
tested for the human ribonuclease P gene (constitutive gene) as an internal control. 
Screening for influenza B was simultaneously done by Flu–B matrix gene specific primers 
and probe. The positive controls for each virus were made of RNA extracts from non 
infectious material for use with the CDC RT-PCR method for detection and characterization 
of human seasonal influenza viruses. Water was used as a negative control.
Subsequently, influenza A positive samples were tested to identify the influenza subtypes 
A(H3N2) or A(H1N1)pdm09 using a single one step real-time RT-PCR with six pairs of 
primers and probes for the specific detection of influenza A subtypes. The specific HA 
genes for each influenza A subtype were amplified: seasonal A(H1N1) and A(H3N2), 
pandemic A(H1N1)pdm09 and avian A(H5N1) and A(H7N9) according to CDC protocol 
[24]. Influenza isolates with a Cycle threshold (Ct <30) were frozen and shipped in dry ice 
to the CDC in Atlanta for genetic and antigenic characterization.
• Inoculation into Cell Culture—Among all 32 samples sent to the CDC Atlanta, 23 
specimens contained sufficient volume to be inoculated into Madin Darby Canine Kidney 
(MDCK) or MDCK SIAT-1 cell culture.
• Hemagglutination and Neuraminidase Inhibition Assays—The antigenic analysis 
using the hemagglutination inhibition (HI) assay was performed on all virus isolates having 
sufficient hemagglutination (HA) titer. Viruses were tested by HI with post-infection ferret 
antisera to the vaccine strain as well as representative reference viruses from circulating 
genetic groups. Influenza A(H3N2) viruses were tested with 0.75% guinea pig red blood 
cells (RBCs) in the presence of 20 μM oseltamivir and A(H1N1)pdm09 viruses were tested 
with 0.5% turkey RBCs.
The neuraminidase inhibition assay was performed to assess the virus susceptibility to the 
NA inhibitors oseltamivir and zanamivir, as previously described [25].
2.4. Sequencing and Genetic Characterization
In collaboration with the INRB, selected influenza A(H3N2) and A(H1N1)pdm09 virus 
isolates from DRCongo were sent to CDC in Atlanta for sequencing and genetic 
characterization. The influenza genome was amplified with SuperScript III One-Step RT-
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PCR with Platinum Taq High Fidelity (Invitrogen) using the Uni/Inf primer set as previously 
described [26]. Indexed paired-end libraries were generated from the amplicons by utilizing 
Nextera XT Sample Preparation Kit (Illumina, San Diego, CA) according to manufacturer’s 
protocol. Libraries were sequenced on the Illumina MiSeqwith a MiSeq v2 300 cycle kit. 
Reads were assembled and consensus sequences were generated using Iterative Refinement 
Meta-Assembler (IRMA) [27].
Phylogenetic analyses were done to genetically characterize influenza virus isolates 
collected at the DRC and to compare them with the vaccine strains recommended by WHO 
during the 2014-2016 influenza seasons. First, reference tree data sets for A(H1N1)pdm09 
and A(H3N2) viruses were created by selecting reference viruses from WHO vaccine 
selection meeting reports since 2012 and their HA nucleotide sequences were down loaded 
from the Global Initiative on Sharing Avian Influenza (GISAID) database [28], as shown in 
the Supplementary Table 1. In addition, GISAID was searched to download the HA gene 
sequences of A(H1N1)pdm09 and A(H3N2)virus isolates collected in Africa from August to 
December, 2014. Virus HA sequences from the DRC and other African countries were 
aligned against the A(H3N2) or A(H1N1)pdm09 WHO reference data sets using MUSCLE 
[29] and trimmed to the beginning of the mature HA protein gene sequence using BioEdit 
v7.2.5 [30].
The TREESUB phylogenetic program [31] was used to estimate maximum likelihood 
phylogenetic trees using RAxML and PAML, followed by branch annotation of amino acid 
substitutions. Briefly, stop codons were trimmed from the aligned sequences in BioEdit and 
the vaccine virus was placed at the top of the alignment to be used as the tree out group and 
reference sequence. The general time reversible + Γ(GTR+GAMMA) nucleotide 
substitution model was selected in RAxMLv.7.3.0f or tree inference [32]. Ancestral codon 
substitutions for each gene were estimated using base ml, as implemented in PAML [33], 
using the ML trees inferred. Non synonymous substitutions were then transcribed on to the 
consensus gene phylogenies and visualized in FigTree v1.4.2 [34]. Nucleotide sequences 
from DRCongo used in this study were entered into the GISAID EpiFlu database and 
accessions are provided in the Supplementary Table 2.
3. Results
From August to December 2014, 806 samples were collected in DRCongo from which 61 
were positive for influenza A (Table 1, Figure 1). During this reporting period, no influenza 
B specimens were detected (Table 1). Only 32 of the 61 influenza A positive samples from 
different surveillance sites in DRC had a Ct < 30 and these samples were selected and 
shipped to CDC in Atlanta for antigenic and genetic characterization. Results from this 
study showed that among the 32 samples tested: 26 were influenza A(H3N2), 2 were 
influenza A(H1N1)pdm09, 2 had insufficient volume for testing and 2 samples were 
negative for influenza by RT-PCR, as shown in Table 2.
• A(H3N2) influenza virus
The majority of A(H3N2) influenza viruses did not have sufficient HA titer to be 
antigenically characterized by HI. Either full HA sequencing or limited pyrosequencing was 
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done on viruses with insufficient HA titer for HI testing for genetic characterization only. 
Limited pyrosequencing was also done on A(H3N2) viruses not recovered in cell culture. 
Among the four A(H3N2) viruses tested by HI, one was antigenically similar to the A/
Texas/50/2012 vaccine virus, while three were poorly inhibited by ferret antisera raised 
against A/Texas/50/2012 (Table 2). The majority of influenza A(H3N2) viruses tested from 
the DRC were antigenically related to the A/Switzerland/9715293/2013 vaccine virus. All 
A(H3N2) viruses tested from DRC were sensitive to oseltamivir and zanamivir.
The A(H3N2) phylogenetic tree was divided into 7 genetic groups based on shared amino 
acid (AA) changes when compared to the previous vaccine strain A/Perth/16/2009 (data not 
shown). Genetic analysis shows that genetic group 3 (V223I) was further divided into 
subgroups 3A (N144D, N145S, D487N), 3B (N145S, A198S, N312S, D487N) and 3C 
(A198S, N312S). Viruses from group 3C (S45N, T48I) diverged into genetic subgroups 3C.
1, 3C.2 (Q33R, N145S, N278K, D489N) and 3C.3 (Q33R, T128A, R142G, N145S, 
N278K). Figure 2 shows the A(H3N2) phylogenetic tree since the divergence of groups 3C.2 
and 3C.3 with A/Texas/50/2012 vaccine virus as outgroup. The amino acid differences 
against A/Texas/50/2012 reference virus are shown in Table 3. Group 3C.2 was divided into 
two genetic subgroups: 3C.2a (L3I, N144S, F159Y, K160T, N225D, Q311H) and 3C.2b 
(with AA changes found in group 3C.2a, except for F159Y). Group 3C.3 was split into 
subgroups 3C.3a (A138S, F159S, N225D, K326R) and 3C.3b (E62K, K83R, N122D, 
L157S, R261Q, V347K). Sequencing and phylogenetic analysis of A(H3N2) isolates from 
DRC confirmed that these viruses belonged to genetic group 3C.2a (n=6) and 3C.3 (n=2), as 
depicted in Table 3 and Figure 2.
• A(H1N1)pdm09 influenza viruses
Two influenza A(H1N1)pdm09 isolates from the DRCongo were antigenically characterized 
as A/California/07/2009-like, the recommended A(H1N1)pdm09 component of the northern 
and southern hemisphere influenza vaccine formulations since 2009. The A(H1N1)pdm09 
phylogenetic tree was divided into 9 major genetic groups (data not shown). The majority of 
the A(H1N1)pdm09 viruses isolated worldwide in 2014 belonged to genetic group 6. 
Genetic group 6 (D97N, S185T, S203T, E374K, S451N) had diverged into subgroups 6A 
(H138R, V249L), 6B (K163Q, A256T, K283E, E499K) and 6C (V2341, K283E, E499K). 
The A(H1N1)pdm09 DRC isolates (n=2) were classified as group 6B viruses and are 
represented in Table 4. All A(H1N1)pdm09 viruses tested from DRC were sensitive to 
oseltamivir and zanamivir.
4. Discussion
The main objective of this study was to identify and characterize influenza viruses 
circulating in the Democratic Republic of Congo in 2014. To the best of our knowledge, this 
kind of work has never been done in the DRCongo, while other African countries like 
Madagascar, Morocco and Egypt, have worked on the improvement of their surveillance 
system capacity to understand the molecular epidemiology and disease burden caused by 
circulating influenza viruses [35].
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Our findings showed that the influenza activity in DRCongo increased during the month of 
November of 2014, reaching its peak on December the same year. Of note is that influenza 
activity was concomitant with the September - April rainy season in DRC, as previously 
described for the 2009-2011 seasons [36]. Similar results were found in Senegal (Dakar), 
Côte d’Ivoire (Abidjan), and Niger (Niamey) probably because of lower temperatures, as 
described elsewhere for Niger in 2010 [36]. This same pattern has also been observed in the 
north eastern part of tropical Brazil (Fortaleza) [37].
A total of 32 virus samples collected at the DRC from August to December of 2014 were 
shipped to the CDC in Atlanta, from which 20 were genetically characterized by either full 
genome sequencing or limited pyrosequencing. Limited pyrosequencing was done in 
A(H3N2) virus isolates which had insufficient HA titer for HI testing or when viruses were 
not recovered in cell culture.
Sixteen of the A(H3N2) viruses isolated at the DRC belonged to genetic group3C.2a and 
two isolates to group 3C.3. Four of these isolates were antigenically similar to the A/
Switzerland/9715293/2013 virus, the recommended A(H3N2) vaccine component during the 
2015-2016 influenza season. In 2013, the majority of A(H3N2) viruses tested was 
antigenically similar to the A/Texas/50/2012 vaccine virus. After the WHO northern 
hemisphere vaccine selection meeting in February 2014, antigenic drift was detected in 
viruses from genetic group 3C, giving rise to subgroups 3C.2a and 3C. 3a. Ferret antisera 
raised against A/Texas/50/2012 vaccine virus showed a reduction in HA titer, with the 
concomitant worldwide increase of 3C.2a and 3C.3a groups from 2014 to date. Despite the 
genetic diversity, the majority of 3C.2a and 3C.3a viruses were antigenically similar to the 
new A/Switzerland/9715293/2013 vaccine virus.
Other A(H3N2) HA sequences from African countries, including Algiers, Dakar, 
Madagascar, Ethiopia, Ghana and Tanzania, available from the GISAID Epiflu database, 
were classified as 3C.3a, and one isolate from Egypt was found to cluster with other 3C.3b 
viruses (figure 2). No DRC A(H3N2) isolates from genetic groups 3C.3a and 3C.3b were 
collected in 2014. However, similarly to the DRC, 3C.3 viruses were also found in Zambia 
and Kenya after GISAID EpiFlu database searching. Based on the close proximity of East 
African countries with 3C.3a viruses in circulation, we expect the further expansion of the 
3C.3a group to the DRC.
Two A(H1N1)pdm09 isolates from the DRC were classified under genetic group 6B and 
were antigenically indistinguishable to the A/California/07/2009 virus, which remains the 
WHO A(H1N1)pdm09 influenza vaccine component since 2009. The A(H1N1)pdm09 HA 
sequences from Ethiopia and Egypt, also available from the GISAID Epiflu database, 
clustered with other 6B virus sequences as well. Interestingly, Ghana was the only African 
country found to have viruses from genetic group 6C in circulation since the summer of 
2014 and the reason why further expansion was not observed at the time remains to be 
elucidated.
Ferret antisera raised against the A/California/07/2009 vaccine virus showed reduced HA 
titers with a small number of isolates during the 2014-2015 influenza season. These 
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A(H1N1)pdm09 low-reactors often had amino acid changes in HA positions 153-157 and 
may have acquired these changes through cell culture, which is consistent with results 
obtained since May 2009. African isolates were not found to have amino acid changes in HA 
positions 153-157, confirming that no antigenic change has taken place, as established by 
the antigenic analysis data.
5. Conclusion
Influenza A(H3N2) and A(H1N1)pdm09 viruses have continued to circulate worldwide 
since their emergence and are expanding at high levels in most countries. Molecular 
surveillance year-round, especially in sub and tropical areas of Africa, is critical for 
improving vaccine strategies for the prevention and control of influenza illness. It is also 
important in contributing to the understanding of genetic variations and in the early 
detection of antigenic drift.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Number of DRCongo isolates positive for influenza and characterized at the CDC Atlanta. 
Thirty-two DRC samples which were positive for influenza A and had Ct <30 were selected 
for antigenic and genetic characterization.
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Figure 2. 
Representative hemagglutinin ML phylogenetic tree of A(H3N2) viruses collected since 
2013. The A/Texas/50/2012 (underlined, bold) was used as reference in TREESUB to 
estimate ML phylogenetic trees via RAxML and PAML, and for automated annotation of 
amino acid substitutions in the nexus format. The consensus HA tree and the transcribed 
amino acid substitutions were visualized in FigTree. The scale bar represents the average 
number of nucleotide substitutions per site. Genetic groups 3C.2 and 3C.3, with the 
respective subgroups are represented in the tree. DRCongo isolates (bold) grouped with 3C.
2a and 3C.3 reference viruses. Other African isolates clustered with the A/Switzerland/
9715293/2013 (underlined, bold) vaccine virus from genetic group 3C.3a.
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Figure 3. 
Representative hemagglutinin ML phylogenetic tree of A(H1N1)pdm09 viruses collected 
since 2009. The A/California/07/2009 (underlined, bold) was used as reference in 
TREESUB to estimate ML phylogenetic trees via RAxML and PAML, and for automated 
annotation of amino acid substitutions in the nexus format. The consensus HA tree and the 
transcribed amino acid substitutions were visualized in FigTree. The scale bar represents the 
average number of nucleotide substitutions per site. Genetic groups 6, 7 and 9 are depicted 
in the tree. DRCongo isolates (bold) clustered with viruses from genetic subgroup 6B.
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Table 2
Samples from DRCongo characterized at the CDC Atlanta
Influenza Subtype Number of sample Characterization
A(H1N1)pdm09
2 A/California/07/2009-likeA(H1N1)pdm09
1 Insufficient volume for testing
A(H3N2)
1 A/Texas/50/2012-likeA(H3N2)GP
3 A/Texas/50/2012-likeA(H3N2)
12 Influenza A(H3N2)
10 Influenza A(H3)
1 Insufficient volume for testing
Negative 2 Negative by PCR for influenza
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